You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOsanetant
Accession NumberDB04872
TypeSmall Molecule
GroupsInvestigational
DescriptionDeveloped by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • SR 142801
  • SR-142801
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIK7G81N94DT
CAS number160492-56-8
WeightAverage: 606.625
Monoisotopic: 605.257582985
Chemical FormulaC35H41Cl2N3O2
InChI KeyDZOJBGLFWINFBF-UMSFTDKQSA-N
InChI
InChI=1S/C35H41Cl2N3O2/c1-27(41)38(2)35(29-13-7-4-8-14-29)19-23-39(24-20-35)21-9-17-34(30-15-16-31(36)32(37)25-30)18-10-22-40(26-34)33(42)28-11-5-3-6-12-28/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3/t34-/m0/s1
IUPAC Name
N-(1-{3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl)-N-methylacetamide
SMILES
CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C2=CC=CC=C2)C2=CC(Cl)=C(Cl)C=C2)CC1)C1=CC=CC=C1
Pharmacology
IndicationPotential therapy for schizophrenia, depression and visceral pain.
Structured Indications Not Available
PharmacodynamicsOsanetant is a neurokinin-3 (NK3) receptor antagonist. Preliminary clinical trials have demonstrated that osanetant is superior to placebo on global assessment of efficacy and measures of positive symptoms in schizophrenia.
Mechanism of actionThe mechanism of action of osanetant is uncertain at this point. Various preclinical data indicate that activation of NK3 receptors enhances the release of biogenic amines, including dopamine and serotonin. NK3 receptor antagonists could block NK3-receptor-mediated activation of these systems.
TargetKindPharmacological actionActionsOrganismUniProt ID
Neuromedin-K receptorProteinunknownNot AvailableHumanP29371 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Osanetant is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineOsanetant may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineOsanetant may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineOsanetant may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineOsanetant may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Osanetant.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Osanetant.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Osanetant.Approved
adipiplonThe risk or severity of adverse effects can be increased when Osanetant is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Osanetant is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Osanetant is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Osanetant.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Osanetant.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Osanetant.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Osanetant.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Osanetant is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Osanetant is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Osanetant.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Osanetant is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Osanetant is combined with Amperozide.Experimental
AmphetamineOsanetant may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Osanetant.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Osanetant is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Osanetant is combined with Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Azaperone.Vet Approved
AzelastineOsanetant may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Osanetant is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Osanetant is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Osanetant.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Osanetant is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Osanetant.Approved
BenzphetamineOsanetant may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Osanetant is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Osanetant is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Osanetant.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Osanetant.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Osanetant is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Osanetant is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Osanetant.Approved, Investigational
BuprenorphineOsanetant may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Osanetant.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Osanetant.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Osanetant is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Osanetant is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Osanetant is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Osanetant.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Osanetant.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Osanetant.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Osanetant.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Osanetant is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Osanetant.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Osanetant is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Osanetant is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Osanetant.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Osanetant.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Osanetant.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Osanetant.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Osanetant is combined with Chlorphenamine.Approved
ChlorphentermineOsanetant may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Osanetant.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Osanetant.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Osanetant.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Osanetant.Approved
ClemastineThe risk or severity of adverse effects can be increased when Osanetant is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Osanetant is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Osanetant is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Osanetant is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Osanetant is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Osanetant is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Osanetant.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Osanetant.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Osanetant.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Osanetant.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Osanetant is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Osanetant.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Osanetant is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Osanetant is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Osanetant.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Osanetant is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Osanetant is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Osanetant.Approved
DesipramineThe risk or severity of adverse effects can be increased when Osanetant is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Osanetant is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Osanetant.Approved
DetomidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Osanetant is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Osanetant.Approved, Vet Approved
DextroamphetamineOsanetant may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Osanetant.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Osanetant.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Osanetant.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Osanetant.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Osanetant.Approved, Illicit, Vet Approved
DiethylpropionOsanetant may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Osanetant is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Osanetant.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Osanetant.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Osanetant.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Osanetant.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Osanetant is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Osanetant.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Osanetant.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Osanetant is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Osanetant is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Osanetant is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Osanetant.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Osanetant.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Osanetant.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Osanetant.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Osanetant.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Osanetant is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Osanetant is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Osanetant.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Osanetant.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Osanetant is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Osanetant.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Osanetant.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Osanetant.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Osanetant.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Osanetant.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Osanetant.Approved
EthanolOsanetant may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Osanetant.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Osanetant is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Osanetant is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Osanetant.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Osanetant.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Osanetant.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Osanetant is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Osanetant is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Osanetant is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Osanetant.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Osanetant.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Osanetant is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Osanetant is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Osanetant.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Osanetant.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Osanetant is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Osanetant is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Osanetant.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Osanetant is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Osanetant.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Osanetant.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Osanetant.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Osanetant.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Osanetant.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Osanetant.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Osanetant is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Osanetant.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Osanetant is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Osanetant is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Osanetant.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Osanetant.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Osanetant is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Osanetant.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Osanetant is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Osanetant.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Osanetant is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Osanetant.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Osanetant.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Osanetant.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Osanetant.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Osanetant.Approved
HydrocodoneOsanetant may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Osanetant.Approved, Illicit
Hydroxyamphetamine hydrobromideOsanetant may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Osanetant is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Osanetant is combined with Indalpine.Investigational, Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Osanetant.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Osanetant.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Osanetant.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Osanetant.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Osanetant is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Osanetant is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Osanetant.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Osanetant is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Osanetant is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Osanetant is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Osanetant.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Osanetant.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Osanetant.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Osanetant.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Osanetant.Approved, Investigational
LisdexamfetamineOsanetant may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Osanetant.Approved
LofentanilThe risk or severity of adverse effects can be increased when Osanetant is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Osanetant is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Osanetant.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Osanetant.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Osanetant.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Osanetant is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Osanetant is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Osanetant is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Osanetant.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Melperone.Approved
MephedroneOsanetant may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineOsanetant may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Osanetant.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Osanetant.Approved, Illicit
MequitazineOsanetant may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Osanetant.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Osanetant is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Osanetant.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Osanetant.Approved, Illicit
MethamphetamineOsanetant may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Osanetant.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Osanetant.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Osanetant is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Osanetant.Approved
MethotrimeprazineOsanetant may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Osanetant.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Osanetant is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Osanetant is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Osanetant.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Osanetant.Approved, Investigational
MetyrosineOsanetant may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Osanetant.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Osanetant.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Approved, Investigational
MirtazapineOsanetant may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAOsanetant may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Osanetant.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Osanetant.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Osanetant.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Osanetant.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Osanetant.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Osanetant.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Osanetant.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Osanetant is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Osanetant is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Osanetant.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Osanetant is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Osanetant.Approved
OpiumThe risk or severity of adverse effects can be increased when Osanetant is combined with Opium.Approved, Illicit
OrphenadrineOsanetant may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Osanetant.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Osanetant is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Osanetant.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Osanetant.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Osanetant.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Osanetant.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Osanetant.Approved
ParaldehydeOsanetant may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Osanetant.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Osanetant.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Osanetant.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Approved
PerazineThe risk or severity of adverse effects can be increased when Osanetant is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Osanetant is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Osanetant.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Osanetant.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Osanetant.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Osanetant.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Osanetant is combined with Phenoxyethanol.Approved
PhentermineOsanetant may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Osanetant is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Osanetant.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Osanetant is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Osanetant is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Osanetant is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Osanetant is combined with Pomalidomide.Approved
PramipexoleOsanetant may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Osanetant is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Osanetant.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Osanetant.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Osanetant is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Osanetant.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Osanetant.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Osanetant.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Osanetant.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Osanetant.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Osanetant is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Osanetant.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Osanetant.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Osanetant is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Osanetant is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Osanetant is combined with PSD502.Investigational
PseudoephedrineOsanetant may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Osanetant.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Osanetant.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Osanetant.Approved
RacloprideThe risk or severity of adverse effects can be increased when Osanetant is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Osanetant is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Osanetant.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Osanetant.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Osanetant.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Osanetant.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Osanetant.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Osanetant is combined with Ritanserin.Investigational
RitobegronOsanetant may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Osanetant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Romifidine.Vet Approved
RopiniroleOsanetant may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Osanetant.Approved
RotigotineOsanetant may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Osanetant.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Osanetant.Experimental
Sage 547The risk or severity of adverse effects can be increased when Osanetant is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Osanetant is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Osanetant.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Osanetant.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Osanetant is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Osanetant.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Osanetant.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Approved
StiripentolThe risk or severity of adverse effects can be increased when Osanetant is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Osanetant.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Osanetant is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Osanetant.Approved, Investigational
SuvorexantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Osanetant is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Osanetant is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Osanetant.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Osanetant.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Osanetant.Approved
TetracaineThe risk or severity of adverse effects can be increased when Osanetant is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Osanetant is combined with Tetrodotoxin.Investigational
ThalidomideOsanetant may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Osanetant.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Osanetant.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Osanetant.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Osanetant.Approved
TiagabineThe risk or severity of adverse effects can be increased when Osanetant is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Osanetant is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Osanetant is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Osanetant is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Osanetant is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Osanetant.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Osanetant.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Osanetant.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Osanetant.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Osanetant.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Osanetant.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Osanetant.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Osanetant is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Osanetant is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Osanetant.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Osanetant.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Osanetant is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Osanetant.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Osanetant is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Osanetant is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Osanetant.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Osanetant is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Osanetant.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Osanetant is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Osanetant.Approved, Investigational
ZolpidemOsanetant may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Osanetant is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Osanetant.Approved
ZotepineThe risk or severity of adverse effects can be increased when Osanetant is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Osanetant.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Kronenberg G, Berger P, Tauber RF, Bandelow B, Henkel V, Heuser I: Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry. 2005 Jan;38(1):24-9. [PubMed:15706463 ]
  2. Kamali F: Osanetant Sanofi-Synthelabo. Curr Opin Investig Drugs. 2001 Jul;2(7):950-6. [PubMed:11757797 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9486
Blood Brain Barrier+0.9882
Caco-2 permeable+0.5767
P-glycoprotein substrateSubstrate0.6866
P-glycoprotein inhibitor IInhibitor0.7694
P-glycoprotein inhibitor IIInhibitor0.837
Renal organic cation transporterInhibitor0.5525
CYP450 2C9 substrateNon-substrate0.8013
CYP450 2D6 substrateNon-substrate0.6861
CYP450 3A4 substrateSubstrate0.7427
CYP450 1A2 substrateNon-inhibitor0.9532
CYP450 2C9 inhibitorNon-inhibitor0.9439
CYP450 2D6 inhibitorInhibitor0.5109
CYP450 2C19 inhibitorNon-inhibitor0.8248
CYP450 3A4 inhibitorNon-inhibitor0.703
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7353
Ames testNon AMES toxic0.7977
CarcinogenicityNon-carcinogens0.8292
BiodegradationNot ready biodegradable0.994
Rat acute toxicity2.8030 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9523
hERG inhibition (predictor II)Inhibitor0.8584
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000154 mg/mLALOGPS
logP6.47ALOGPS
logP6.27ChemAxon
logS-6.6ALOGPS
pKa (Strongest Basic)9.3ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.86 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity172.73 m3·mol-1ChemAxon
Polarizability66.11 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1-benzoylpiperidines. These are compounds containing a piperidine ring substituted at the 1-position with a benzoyl group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoyl derivatives
Direct Parent1-benzoylpiperidines
Alternative Parents
Substituents
  • 1-benzoylpiperidine
  • N-benzoylpiperidine
  • Phenylpiperidine
  • Phenylbutylamine
  • Piperidinecarboxylic acid
  • N-acyl-piperidine
  • Benzoic acid or derivatives
  • Benzamide
  • 1,2-dichlorobenzene
  • Aralkylamine
  • Halobenzene
  • Chlorobenzene
  • 4-aminopiperidine
  • Piperidine
  • Aryl halide
  • Aryl chloride
  • Acetamide
  • Tertiary carboxylic acid amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Tachykinin receptor activity
Specific Function:
This is a receptor for the tachykinin neuropeptide neuromedin-K (neurokinin B). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: neuromedin-K > substance K > substance P.
Gene Name:
TACR3
Uniprot ID:
P29371
Molecular Weight:
52201.35 Da
References
  1. Tian G, Wilkins D, Scott CW: Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition. Mol Pharmacol. 2007 Mar;71(3):902-11. Epub 2006 Dec 15. [PubMed:17172464 ]
Comments
comments powered by Disqus
Drug created on October 20, 2007 04:46 / Updated on August 17, 2016 12:24